Ph: (740) 356-7490 Fx: (740) 356-7488

## Anifrolumab (Saphnelo) Order Form

PATIENT & PRESCRIBER INFORMATION					
Patient Name:		DOB:Pho	ne: (H)	(C)	
Patient Address:					
Ht.: Wt.:					
Prescriber Name/Title:		Address:			
		Prescriber NPI #:			
REQUIRED: Most Recent H&P, notes should include any past	· ·	•	•	•	
	DIAGNOSIS, CLIN	IICAL INFORMATION,	& PRESCRIPTION		
☑ May substitute mandated o	r preferred biosimilar as n	ecessary.			
☑ Infusion rates will follow ma	anufacturer recommendat	ions.			
☑ In the event of an adverse reaction, line maintenance/flushes, or O2 are required, the SOMC AIC established protocols will be utilized.					
☑ Monitor for any adverse even	ents post administration fo	or at least 30 minutes or un	til clinically stable.		
Pre-Treatment Medications	: (Check all that apply) To	be administered 30 minu	ites prior to each admini	istration.	
☐Acetaminophen (Tylenol)	650 mg by mouth x 1 dos	e			
□25 mg / □ 50 mg Diphen	hydramine (Benadryl) 🗖	PO or 🛘 IV x 1 dose			
☐Methylprednisolone (Solu	imedrol) 100 mg IVP x 1 d	ose			
☐Other (Please Specify)					
		AND			
<b>Diagnosis</b> (Check all that apply	y)				
		П	<b>—</b> • • • • • • • • • • • • • • • • • • •		
Systemic Lupus	Systemic Lupus	☐ Endocarditis in	Pericarditis in	Lung Involvement	
Erythematosus (SLE), unspecified	Erythematosus (SLE), organ or system	Systemic Lupus Erythematosus (SLE)	Systemic Lupus Erythematosus (SLE)	in Systemic Lupus Erythematosus (SLE)	
urispecified	involvement	Erythematosus (SEE)	Erythematosus (SLE)	Erythematosus (SLE)	
	unspecified				
☐ Glomerular disease	☐ Tubulo-interstitial	Other ergan er	☐ Other forms of	☐ Other	
in Systemic Lupus	nephropathy in	☐ Other organ or system involvement in		□ Other	
Erythematosus (SLE)		Systemic Lupus	Erythematosus (SLE)		
	Erythematosus (SLE)		(==		
<u>Dose</u> :					
☐ Anifrolumab (Saphnel	o) 300 mg IV every 4 wee	ks, x 1 year			
Additional order(s)					
Lab order(s)					
☐ CBC ☐ at eac	· <del></del>				
☐ CBC w/ Diff ☐ at eac	· <del></del>				
☐ CMP ☐ at eac	<i>,</i> —				
☐ Other –					
	PROVI	DER: DATE: TIME:	SIGNATURE:		



**ANIFRO** 

Created: 02/02/24	P & T Comm.	
Reviewed & Approved	04/29/24	
Next Review Date	04/29/24	
Version	V04292024.0	